55.00 +0.36 (0.66%)
Pre-market: 8:00AM EDT
|Bid||54.65 x 200|
|Ask||54.95 x 600|
|Day's range||54.52 - 54.91|
|52-week range||37.38 - 55.43|
|PE ratio (TTM)||76.51|
|Earnings date||18 Oct 2017|
|Dividend & yield||1.06 (1.94%)|
|1y target est||56.56|
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
ABBOTT PARK, Illinois, Oct. 16, 2017 /PRNewswire/ -- Abbott (ABT) today announced the U.S. launch of the company's Proclaim™ DRG Neurostimulator System, a new device designed to deliver stimulation to the dorsal root ganglion (DRG) and alleviate pain in patients suffering from complex regional pain syndrome (CRPS) of the lower limbs. With the Proclaim DRG system, Abbott has added new, patient-centric benefits to a device capable of delivering the company's sustained and superior pain relief for patients battling CRPS.
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
On October 18, 2017, Abbott Laboratories will release its 3Q17 earnings results. Abbott stock was trading at its 52-week high of $55.4 on October 10.
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.
Oct (Shenzhen: 000069.SZ - news) 10 (Reuters) - Pfizer (NYSE: PFE - news) said on Tuesday it was considering the sale or spin-off of its consumer healthcare business, shaking up the industry and potentially putting a headache pill to lip balm operation worth some $15 billion up for grabs. The move comes as Germany's Merck KGaA (LSE: 0O14.L - news) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years.
The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.
QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.
Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.
A pacemaker for the brain can be used to treat symptoms of neurological disorders like Parkinson’s Disease.
ABBOTT PARK, Illinois, Oct. 4, 2017 /PRNewswire/ -- Abbott (ABT) announced today that it has successfully completed its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price (the "Offer Price") of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the "Offer"). The Offer was made in connection with Abbott's previously announced agreement to acquire Alere, which closed on Oct. 3, 2017. American Stock Transfer & Trust Company, LLC, the depositary for the Offer (the "Depositary"), has advised Abbott that as of the Expiration Time, 1,748,025 shares of Preferred Stock had been tendered in the Offer, representing approximately 98.5 percent of the outstanding shares of Preferred Stock.
Abbott (ABT) announced the FDA approval of its Freestyle Libre on September 27, and some analysts have updated their recommendations.
On August 30, ABT announced the regulatory approval for its dydrogesterone oral medication in Russia and the Netherlands for invitro fertilization treatment.
On September 22, 2017, Abbott Laboratories (ABT) announced the FDA approval of the MR-conditional labeling for its Ellipse ICD.